Findings highlight the Pfizer-BioNTech vaccine’s role in preventing MIS-C, a rare post-COVID inflammatory syndrome in ...
Pfizer elected to out-license the drug 11 months ago to avoid research and development costs. But Roivant's expenses to develop the treatment, which targets an inflammatory protein called TL1A ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback